Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spago Nanomedical ABOSTO:SPAGO -1.30%34 Interest Coverage is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates OSTO:SPAGO with a GF Score™ of 34/100 and a GF Value™ of kr0.03 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 376 Biotechnology companies, Spago Nanomedical AB ranks worse than 265957.18% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Spago Nanomedical AB's
Operating Income
for the
three
months ended in Mar. 2026 was kr-6.90 Mil. Spago Nanomedical AB's Interest Expense for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Spago Nanomedical AB has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Spago Nanomedical AB has no debt.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Spago Nanomedical AB's Interest Coverage or its related term are showing as below:
OSTO:SPAGO's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.135 * Ranked among companies with meaningful Interest Coverage only.
Spago Nanomedical AB (OSTO:SPAGO) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Spago Nanomedical AB Interest Coverage Related Terms
Spago Nanomedical AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for Spago Nanomedical AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
OSTO:SPAGO vs VRTX, REGN, RVMD: Interest Coverage Comparison
For the Biotechnology subindustry, Spago Nanomedical AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spago Nanomedical AB Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Spago Nanomedical AB's Interest Coverage falls into.
Spago Nanomedical AB Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Spago Nanomedical AB (OSTO:SPAGO) has a Interest Coverage of No Debt (1) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Spago Nanomedical AB and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, Spago Nanomedical AB's Interest Coverage has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, Spago Nanomedical AB ranks #999999 out of 376 companies in the Biotechnology industry.
Is Spago Nanomedical AB's Interest Coverage too high?
Spago Nanomedical AB's current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, Spago Nanomedical AB ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spago Nanomedical AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Spago Nanomedical AB ranks #999999 out of 376 companies for Interest Coverage. This places Spago Nanomedical AB in the lower half of its industry. The industry median Interest Coverage is 106.14. Historically, Spago Nanomedical AB's own Interest Coverage has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.14, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Spago Nanomedical AB and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spago Nanomedical AB's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Based on GuruFocus' analysis, Spago Nanomedical AB (OSTO:SPAGO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.03, compared to a current price of kr0.11 — trading 278.3% above its estimated fair value. The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Spago Nanomedical AB's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Spago Nanomedical AB (OSTO:SPAGO), the current Interest Coverage is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spago Nanomedical AB (OSTO:SPAGO) Overvalued in 2026?
Based on GuruFocus' analysis, Spago Nanomedical AB stock appears to be overvalued.
The current stock price of kr0.11 is trading 278.3% above its estimated GF Value™ of kr0.03.
GuruFocus considers Spago Nanomedical AB to be Significantly Overvalued.
Key valuation signals for OSTO:SPAGO:
Interest Coverage: No Debt (1) (100% below median its 10-year median of 10,000.00)
GF Value™: kr0.03 vs. price of kr0.11 (278.3% above fair value)
No single metric tells the full story. See the OSTO:SPAGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
34GF Score
Get the complete analysis for OSTO:SPAGO
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPAGO has been successfully added to your 
